Back to search results

Photoacoustic Flow Cytometry (PAFC) for Detecting Blood Clots

This study is testing a new device called Photoacoustic Flow Cytometry (PAFC) to see if it can detect circulating blood clots (CBCs) in people who have or are at high risk for blood clots (thromboembolism). Currently, there isn't a perfect way to find these clots, especially when there are only a few. The PAFC device aims to improve detection, which could help prevent complications. Researchers will compare the number of clots detected by PAFC with D-dimer levels (a blood test for clotting) in participants. You may be able to join if you are 18 or older and have been diagnosed with a blood clot condition. The study plans to enroll 30 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention (the PAFC device). It aims to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints, comparing PAFC detection with D-dimer levels, will be measured at 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05301348

In Vivo Detection of Circulating Clots in Patients With Thromboembolism

Recruiting
NAAges 18+InterventionalDiagnostic
University of Arkansas
~30 participants
Updated 2026-02-19 on ClinicalTrials.gov
What's tested:Photoacoustic Flow Cytometry

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comparison of Circulating blood clots detected by PAFC with D-dimer levels in patients with known venous thromboembolic disease - Positive PA peaks
Measured over 30 days
+1 more outcome measured

Conditions

Thromboembolism

Explore related trials

Thromboembolism

Where it's being run

1 sites across 1 states
Arkansas1

Study leadership

  • Sanjeeva Onteddu, MD · PRINCIPAL_INVESTIGATOR · University of Arkansas
  • Jonathan A Young · STUDY_DIRECTOR · University of Arkansas

Who to contact

Sanjeeva Onteddu, MD
[email protected]
5016865135
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women, 18 years old and older.
Evidence of current venous or arterial thromboembolic disease diagnosed by standard of care clinical, radiographic, or laboratory testing or acute ischemic stroke.
Informed consent provided by the subject.

Exclusion

Pulmonary embolus with a need for mechanical ventilation or other ventilator support (may be on oxygen delivered by nasal cannula or mask at an FiO2 of ≤ 0.40)
Acute coronary syndrome (including unstable angina)
Significant cardiac arrhythmia (may have atrial fibrillation controlled with medication)
Intracardiac thrombus
Any embolus or thrombus requiring vascular surgery or interventional radiology to attempt acute embolectomy or thrombectomy
Sickle cell disease with vaso-occlusive crisis
Sepsis or life-threatening infection
Traumatic injury requiring hospitalization (within 30 days prior to enrollment)
Pregnancy or breastfeeding
Severe mental illness
Other conditions deemed by the investigators to put the subject at greater risk

What this trial measures

  • Comparison of Circulating blood clots detected by PAFC with D-dimer levels in patients with known venous thromboembolic disease - Positive PA peaks30 days

    Measurement of in vivo CBC-associated positive PA peaks in a signal trace of patients who have been diagnosed with conventional methods.

  • Comparison of Circulating blood clots detected by PAFC with D-dimer levels in patients with known venous thromboembolic disease - Negative PA peaks30 days

    Measurement of in vivo CBC-associated negative PA peaks in a signal trace of patients who have been diagnosed with conventional methods.